Reuters logo
BRIEF-European Medicines Agency's CHMP recommends approval for Merck's Keytruda
July 21, 2017 / 11:53 AM / 2 months ago

BRIEF-European Medicines Agency's CHMP recommends approval for Merck's Keytruda

July 21 (Reuters) - Merck & Co Inc

* European Medicines Agency’s CHMP recommends approval for Merck’s Keytruda® (pembrolizumab) for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer

* Says ‍final decision is expected in Q3 of 2017​

* Merck-‍ Positive opinion based on overall survival benefit demonstrated in phase 3 keynote-045 trial, durable responses observed in phase 2 keynote-052 trial​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below